Teandrea McDaniel, NP
Adult Health · Muskegon Heights, MINPI 1598494734
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,739 and has fallen 61.7% since, to $666 in 2025. Among adult health clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 202 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$566
- AbbVie$529
- Novo Nordisk$486
- GSK$456
- Supernus Pharmaceuticals, Inc.$403
- Teva Pharmaceuticals USA, Inc.$267
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,054100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $566 |
| AbbVie | 37 | $529 |
| Novo Nordisk | 24 | $486 |
| GSK | 19 | $456 |
| Supernus Pharmaceuticals, Inc. | 4 | $403 |
| Teva Pharmaceuticals USA, Inc. | 11 | $267 |
| Lilly USA, LLC | 21 | $230 |
| Otsuka America Pharmaceutical, Inc. | 12 | $209 |
| Bayer | 8 | $111 |
| Lundbeck LLC | 5 | $104 |
| Exact Sciences | 4 | $102 |
| Merck | 5 | $88 |
| USWM, LLC | 4 | $76 |
| Neurocrine Biosciences, Inc. | 3 | $64 |
| Pfizer | 3 | $60 |
| Medtronic | 2 | $52 |
| Astellas Pharma US Inc | 2 | $41 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Indivior Inc. | 1 | $19 |
| Tempus AI, Inc | 1 | $18 |
| Vertex | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Abiomed | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$343
- AREXVY$242
- Austedo XR$125
- CAPLYTA$125
- Wegovy$114
How this compares
$4,054 in reported general payments places this provider in the 90th percentile of 527 adult health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 53 | $69,871 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $58,921 |
| TrulicityDulaglutide | 39 | $53,204 |
| MounjaroTirzepatide | 47 | $46,507 |
| JardianceEmpagliflozin | 31 | $44,476 |
| OzempicSemaglutide | 43 | $43,654 |
| FarxigaDapagliflozin Propanediol | 33 | $33,916 |
| TrintellixVortioxetine Hydrobromide | 18 | $16,051 |
| Spiriva HandihalerTiotropium Bromide | 12 | $8,839 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 76 | $8,047 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $5,619 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 167 | $5,565 |
| Duloxetine Hcl | 98 | $5,426 |
| Lurasidone Hcl | 12 | $4,439 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 220 | $3,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $230 | $99,71186 claims |
| PfizerEliquis | $60 | $69,87153 claims |
| GSKTrelegy Ellipta | $456 | $58,92189 claims |
| Boehringer IngelheimJardiance | $15 | $44,47631 claims |
| Novo NordiskOzempic | $486 | $43,65443 claims |
| AstraZenecaFarxiga | $16 | $33,91633 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $16,05118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 527 adult health providers in Michigan.
Other adult health in Muskegon Heights
- Jacqueline BrewerSterling Heights$138K
- Linda Morris McCoyGrand Rapids$59K
- Sarita RaoCanton$51K
- Susanne QuallichAnn Arbor$42K
- Nancy BermanSouthfield$39K
- Michelle MillerQuincy$24K
- Deniene KingAnn Arbor$14K
- Adama JohnsonEastpointe$14K
- Bridget BonelloWyandotte$13K
- Mary KaiserKalamazoo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.